Ajanta Pharma Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹1,375Cr
- +20% YoY
- +1.6% QoQ
- Net profit
- ₹274Cr
- +17.6% YoY
- +5.4% QoQ
- Margin
- 28%
- 0 pp YoY
- +4 pp QoQ
Guidance rank: #85 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Ajanta Pharma expects continued healthy growth momentum across business segments. - India branded business grew 19% in Q3 FY26; gynaecology segment seen as a future growth driver over 2-3 years. - U.S. Full year FY'26 growth guidance: mid-teens revenue growth expected (Page 6). - EBITDA margin expected to maintain at around 27% ±1% for FY'26 (Page 5). - Profit After Tax (PAT) growth: 18% YoY in Q3 FY'26, 14% for 9 months FY'26; PAT margin stable at 20% (Page 5). - U.S.
From Ajanta Pharma's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Ajanta Pharma expects continued healthy growth momentum across business segments.
- India branded business grew 19% in Q3 FY26; gynaecology segment seen as a future growth driver over 2-3 years.
- U.S. generics showed 52% growth in Q3 FY26; 8 product launches in last 12 months; double-digit growth expected in FY27 but likely at a slower pace than FY26.
- Asia branded business projected to deliver mid-single-digit to high-single-digit growth, with some softness expected in certain markets.
- Africa branded business expected to post low-double-digit growth.
- GLP-1 products set to launch in emerging markets from FY27, with first revenue expected around FY28.
- Plans to expand into new geographies (e.g., Latin America) and therapeutic segments to support growth towards $1 billion revenue.
2 more points from Ajanta Pharma's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Ajanta Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capital expenditure during the 9-month period stood at Rs. 235 crores and is expected to be in line with the full-year guidance of around Rs. 300 crores. (Page 5)
- Continued strategic investment in products, brand, and people across the branded generic portfolio is ongoing, as reflected by a 24% increase in other expenses compared to last year. (Page 5)
- There is an increased thrust on acquisitions, which might influence future payout decisions and strategic direction. The Board will decide on this after Q4 results. (Page 9)
2 more points from Ajanta Pharma's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Ajanta Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Ajanta Pharma's call on order book
Create a free account to keep reading this call
Ajanta Pharma — Quarterly revenue & net profit
Ajanta Pharma Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,375 | 1,146 | +20% | 1,354 | +1.6% |
| Operating profit (EBITDA) | 382 | 321 | +19% | 328 | +16.5% |
| Operating margin | 28% | 28% | 0 pp | 24% | +4 pp |
| Profit before tax | 359 | 307 | +16.9% | 341 | +5.3% |
| Net profit (PAT) | 274 | 233 | +17.6% | 260 | +5.4% |
| EPS (₹) | 21.91 | 18.64 | +17.5% | 20.83 | +5.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.8K Cr, net profit ₹388 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Ajanta Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Ajanta Pharma and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Ajanta Pharma Q3 FY26 results?
Ajanta Pharma expects continued healthy growth momentum across business segments. - India branded business grew 19% in Q3 FY26; gynaecology segment seen as a future growth driver over 2-3 years. - U.S. Full year FY'26 growth guidance: mid-teens revenue growth expected (Page 6). - EBITDA margin expected to maintain at around 27% ±1% for FY'26 (Page 5). - Profit After Tax (PAT) growth: 18% YoY in Q3 FY'26, 14% for 9 months FY'26; PAT margin stable at 20% (Page 5). - U.S.
What is Ajanta Pharma share price analysis?
Ajanta Pharma currently shows a neutral. The stock trades at a P/E of 40.1 with a market cap of ₹45,483 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ajanta Pharma planning capital expenditure?
Capital expenditure during the 9-month period stood at Rs. 235 crores and is expected to be in line with the full-year guidance of around Rs. 300 crores.
Keep Ajanta Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
